Caelus Health
Biotech company developing an entirely new class of Microbiome Therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes in people with metabolic syndrome.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
€490k | Grant | ||
| Total Funding | 000k | ||
Related Content
Caelus Health is an Amsterdam-based biotech company specializing in the development and commercialization of microbiota-based products aimed at preventing and treating cardiometabolic disorders, including Type 2 Diabetes. The company leverages its extensive knowledge of the microbiome to create innovative therapeutic solutions. Operating in the healthcare and biotechnology market, Caelus Health serves patients with metabolic syndrome and other unmet medical needs. Its business model focuses on research and development, followed by the commercialization of patented microbiome therapeutics. Revenue is generated through product sales, licensing agreements, and partnerships with other healthcare entities. The company has a strong proprietary position with patents protecting its treatments for Diabetes Mellitus Type 1 and Type 2, cancer cachexia, and autoimmune diseases.
Keywords: microbiome, therapeutics, Type 2 Diabetes, cardiometabolic, biotech, Amsterdam, patented, commercialization, metabolic syndrome, autoimmune.